NCT06908486 Cognitive Bias Modification for Interpretation (CBM-I) in People With Type 2 Diabetes and Persistent Pain
| NCT ID | NCT06908486 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Sydney |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 319 participants |
| Start Date | 2025-04-15 |
| Primary Completion | 2025-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 319 participants in total. It began in 2025-04-15 with a primary completion date of 2025-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to examine the efficacy of cognitive bias modification for interpretation (CBM-I) in people with Type 2 Diabetes and persistent pain. The main question\[s\] it aims to answer is whether interpretation bias training away from pain improves pain outcomes. Participants in the CBM-I group will complete 4 online training sessions approximately half an hour each. Each session will present participants with ambiguous scenarios which may be pain-related, however the final word of the sentence will resolve the scenario as benign (thus training participants to make benign interpretations). A measure of interpretation bias will be administered following the fourth training session, and pain severity and interference will be measured at baseline, post-training, two week follow up, and three month follow up. The study hypothesises that participants in the CBM-I group will demonstrate a greater reduction in the co-primary outcomes of pain severity and pain interference over time compared to those in the placebo control.
Eligibility Criteria
Inclusion Criteria: * Over 18 years of age * Have a diagnosis of Type 2 diabetes. * Have persistent pain (pain present on more days than not, for 3 months or longer). * Score ≥ 3 on average pain severity on the Brief Pain Inventory (BPI). * Fluent in English * Have access to internet and ability to use a computer over a three month period. Exclusion Criteria: * Under 18 years of age * No diagnosis of Type 2 diabetes * No persistent pain * Not fluent in English * No access to internet nor ability to use a computer.
Contact & Investigator
Louise Sharpe
PRINCIPAL INVESTIGATOR
University of Sydney
Frequently Asked Questions
Who can join the NCT06908486 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06908486 currently recruiting?
Yes, NCT06908486 is actively recruiting participants. Contact the research team at tessa.rooney@sydney.edu.au for enrollment information.
Where is the NCT06908486 trial being conducted?
This trial is being conducted at Camperdown, Australia.
Who is sponsoring the NCT06908486 clinical trial?
NCT06908486 is sponsored by University of Sydney. The principal investigator is Louise Sharpe at University of Sydney. The trial plans to enroll 319 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.